Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
The amount is intended to support the company’s growing portfolio of RNA technologies and accelerate efforts to develop various treatment approaches in the gene therapy field.
In an interview with BioSpace, CEO Victoria Richon expressed her excitement about investor support and developing novel, first-in-class treatments.
The new CEO of Freenome has a talent for “making his own weather.” That’s a phrase he heard often growing up in Rapid City, South Dakota and, when applied to his life and career, comes down to assessing himself accurately and looking for opportunities to contribute.
Moderna CEO Stéphane Bancel believes the promise of mRNA vaccines is so great they will become a disruptive force in preventing viral infections.
Kriya Therapeutics, based in Redwood City, Calif. and Research Triangle Park, NC, closed on a Series B financing worth $100 million.
Thermo Fisher Scientific has launched a new collaborative unit that aims to standardize the metabolomics community’s efforts as it engages in more large-scale cohort studies and clinical research.
Kevin Mulleady and Jason Aryeh attempted to back a slate of candidates for the Phoenixus Board of Directors but failed as shareholders overwhelmingly supported the current board.
Through its OrbNet platform, Entos has already forged various partnerships with investors and leaders in the pharmaceuticals, materials, and chemicals industries.
More biopharma companies race toward the Nasdaq this week, while a few rake in cash via private funding rounds.